Patent US5900433A successfully refreshed from Google Patents.
US5900433A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Vascular treatment method and apparatus
Assignee: Cormedics Corp
•
Filing: 1995-06-23
•
Granted: 1999-05-04
•
Expires: 2015-06-23
Abstract
Abstract This invention relates to the method of use of a congener of an endothelium-derived bioactive composition of matter, which comprises administering said congener percutaneously to a site proximately adjacent the exterior of a coronary blood vessel at a therapeutically effective dosage.
Inventors
- 👤 Stephen R. Igo
- 👤 James W. Meador
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-29 19:55
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/557; A61K31/5575; A61K31/13; A61K31/155; A61K31/21; A61M; A61M31/00; A61M2210/00; A61M2210/12; A61M2210/125
Claims Analysis
Total Claims: 24
Claim 1
Independent Claim
37 words
A method of use of a congener of an endothelium-derived bioactive composition of matter, which comprises administering said congener percutaneously to a site proximately adjacent the exterior of a coronary blood vessel at a therapeutically effective dosage.
Claim 2
Independent Claim
37 words
A method of use of a congener of an endothelium-derived bioactive composition of matter, which comprises administering said congener percutaneously to a site proximately adjacent the exterior of a coronary blood vessel at a therapeutically effective dosage.
Claim 3
Dependent Claim
23 words
The method of use of claim 1 in which said congener is prostacyclin, prostaglandin E 1 , a nitrovasodilator, or a combination thereof.
Claim 4
Dependent Claim
23 words
The method of use of claim 2 in which said nitrovasodilator is nitric oxide, a nitric oxide donor agent, or a combination thereof.
Claim 5
Dependent Claim
23 words
The method of use of claim 3 in which said nitric oxide donor agent is L-arginine, sodium nitroprusside, nitroglycerin, or a combination thereof.
Claim 6
Dependent Claim
14 words
The method of use of claim 1 in which said congener is sodium nitroprusside.
Claim 7
Dependent Claim
16 words
The method of use of claim 1 in which said treatment site is a coronary artery.
Claim 8
Dependent Claim
19 words
The method of use of claim 1 in which said treatment site is a vein graft for arterial bypass.
Claim 9
Dependent Claim
27 words
The method of use of claim 1 in which said step of administering includes delivering said congener in a controlled manner over a sustained period of time.
Claim 10
Dependent Claim
24 words
The method of use of claim 1 in which said step of administering comprises intrapericardially extravascularly delivering said congener to said coronary blood vessel.
Claim 11
Dependent Claim
29 words
The method of use of claim 9 in which said step of administering comprises intrapericardially infusing said congener through a percutaneously inserted catheter extravascularly to said coronary blood vessel.
Claim 12
Dependent Claim
24 words
The method of use of claim 1 in which said step of administering comprises transpericardially extravascularly delivering said congener to said coronary blood vessel.
Claim 13
Dependent Claim
29 words
The method of use of claim 11 in which said step of administering comprises transpericardially infusing said congener through a percutaneously inserted catheter extravascularly to said coronary blood vessel.
Claim 14
Dependent Claim
25 words
The method of use of claim 11 in which said step of administering comprises iontophoretically delivering said congener transpericardially extravascularly to said coronary blood vessel.
Claim 15
Dependent Claim
31 words
The method of use of claim 1 in which said step of administering comprises inserting extravascularly to said coronary blood vessel an implant capable of extended time release of said congener.
Claim 16
Dependent Claim
32 words
The method of use of claim 14 in which said step of inserting said extravascular implant comprises percutaneously inserting said implant proximately adjacent, onto, or into the pericardial sac surrounding the heart.
Claim 17
Dependent Claim
29 words
The method of use of claim 14 in which step of inserting said extravascular implant comprises surgically wrapping said implant around a vein graft used for an arterial bypass.
Claim 18
Dependent Claim
20 words
The method of use of claim 14 in which said extravascular implant is a biodegradable controlled-release polymer comprising said congener.
Claim 19
Dependent Claim
55 words
The method of use of claim 1 in which said dosage is effective to provide one or more of the therapeutic effects of promotion of vasodilation, inhibition of vessel spasm, inhibition of platelet aggregation, inhibition of vessel thrombosis, and inhibition of platelet growth factor release, at said treatment sites, without inducing systemic hypotension or anticoagulation.
Claim 20
Dependent Claim
21 words
The method of use of claim 1 in which said dosage is a rate from about 0.1 to about 3.0 μg/kg/min.
Claim 21
Independent Claim
30 words
A method of use of a sodium nitroprusside composition of matter, which comprises percutaneously intrapericardially or transpericardially supplying sodium nitroprusside to a coronary blood vessel in a therapeutically effective dose.
Claim 22
Independent Claim
30 words
A method of use of a sodium nitroprusside composition of matter, which comprises percutaneously intrapericardially or transpericardially supplying sodium nitroprusside to a coronary blood vessel in a therapeutically effective dose.
Claim 23
Independent Claim
33 words
A method of use of a congener of an endothelium-derived bioactive composition of matter which comprises percutaneously intrapericardially or transpericardially delivering said congener to a coronary blood vessel at a therapeutically effective dosage.
Claim 24
Independent Claim
33 words
A method of use of a congener of an endothelium-derived bioactive composition of matter which comprises percutaneously intrapericardially or transpericardially delivering said congener to a coronary blood vessel at a therapeutically effective dosage.
References Cited (Backward Citations)
US3923060A
Cited
US4003379A
Cited
US4346227A
Cited
US5075108A
Cited
US5167960A
Cited
US5069662A
Cited
US5212165A
Cited
US5100392A
Cited
US5236413B1
Cited
US5236413A
Cited
US5140012A
Cited
US5286254A
Cited
US5282785A
Cited
US5213570A
Cited
US5222936A
Cited
US5269326A
Cited
US5304120A
Cited
US5298018A
Cited
US5405919A
Cited
US5403834A
Cited
US5449971A
Cited
US5445039A
Cited
US5681278A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 2002-05-03 | 2002-11-02 | 2003-05-04 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2006-05-03 | 2006-11-02 | 2007-05-04 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2010-05-03 | 2010-11-02 | 2011-05-04 | $7700.00 | Window Closed / Lapsed |